CAS: 941294-54-8; 5-Bromo-2-Methoxynicotinonitrile

该化合物是一种化学化合物,其特点是有刺状环,这是一种六人组成的芳香热循环,含有一个氮原子;5位置有溴原子,2位置有甲氧基,2位置有甲氧基,这有利于其独特的再反应和特性;三位置有西诺组(-CN)增强了其核循环反应的潜力,使其成为有机合成中有价值的中间体.该化合物一般是一种在室温下的固体,可能表现出极地有机溶剂中的中等溶解性.其分子结构表明在制药,农用化学品和材料科学中的潜在应用,特别是在生物活性化合物的开发中.卤素和功能组的存在可以进一步衍生,使其成为合成化学的多用途建筑块.在处理时,应参考安全数据,因为卤化化合物可能对健康造成风险.

英文名称5-Bromo-2-Methoxynicotinonitrile
中文名称5-溴-3-氰基-2-甲氧基吡啶
IUPAC名称5-bromo-2-methoxynicotinonitrile
其它别名5-溴-3-氰基-2-甲氧基吡啶; 5-溴-2-甲氧基-3-氰基吡啶; 5-Bromo-3-Cyano-2-Methoxypyridine
CAS编号941294-54-8
MFCD编号:MFCD09801047
EINECS号:688-572-3
分子式:C7H5BrN2O分子量:213.03
产品CID: 1988098
产品分类有机原料→分子砌块→芳杂环类化合物→吡啶类化合物

相似结构搜索
InChIKey: FRKLCMNRGGZZTQ-UHFFFAOYSA-N
InChI=1S/C7H5BrN2O/c1-11-7-5(3-9)2-6(8)4-10-7/h2,4H,1H3
计算化学: 氢键受体数3.0氢键供体数*可旋转键数1.0

相似化合物

103058-87-3 54916-66-4 88818-88-6

MSDS等安全信息

GHS象形图
GHS符号GHS06 & GHS05;
注释: Skull and crossbones & Corrosion
危险类别急性毒性类别3(经口)
特定目标器官毒性 - 单次接触类别3
皮肤腐蚀/刺激类别2
严重眼损伤类别1
警示词Danger(危险)
危险描述H301 |吞咽会中毒.
H335 |可能引起呼吸道刺激.
H315 |造成皮肤刺激.
H318 |造成严重眼损伤.
防范说明P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P362+P364-P405-P501
危险等级8
UN编号3261.0
危险品标志Xi,T
包装等级Ⅲ
安全声明26-36-45
危险类别码25-36/37/38
WGK Germany3

欧盟法规

C&L通报

上下游产品

CAS号7254-34-4 3-氰基-2-甲氧基吡啶 | CAS号6602-54-6 2-氯烟腈 | CAS号405224-24-0 5-溴-1H-吡唑并[3,4-... | CAS号1073354-05-8 3-氰基-2-甲氧基吡啶-5-...

合成工艺路线路线简述

7254-34-4 = 941294-54-8
反应条件:1.1 Reagents: Sodium Acetate,Bromine Solvents: Acetic Acid; 0 °C; Overnight,70 °C; 70 °C -> Rt
标题:Preparation Of Azaindazole Derivatives And Analogs For Use In The Treatment Of Cancer Overexpressing Trk
参考文献:World Intellectual Property Organization]

7254-34-4 = 941294-54-8
反应条件:1.1 Reagents: Sodium Acetate,Bromine Solvents: Acetic Acid; 12 H,70 °C
标题:3-(4-(Piperazin-1-Yl)Benzamido)-1H-Pyrazolopyridine And Related Compound For Inhibiting Expression Of Melk,And Preparation Method Thereof
参考文献:Korea]

7254-34-4 = 941294-54-8
反应条件:1.1 Reagents: Sodium Acetate,Bromine Solvents: Acetic Acid; 50 °C
标题:Synthesis And Antitumor Activity Evaluation Of 4,6-Disubstituted Quinazoline Derivatives As Novel Pi3K Inhibitors
作者:Hei,Yuan-Yuan; Xin,Minhang; Zhang,Hao; Xie,Xiao-Xiao; Mao,Shuai; Et Al
参考文献:Bioorganic & Medicinal Chemistry Letters 日期:2016 卷标:26(18) 页码:4408-4413]

7254-34-4 = 941294-54-8
反应条件:1.1 Reagents: Sodium Acetate,Bromine Solvents: Acetic Acid; Overnight,70 °C
标题:Preparation Of Azaindazole Derivatives And Analogs For Use In The Treatment Of Pain
参考文献:World Intellectual Property Organization]

7254-34-4 = 941294-54-8
反应条件:1.1 Reagents: Sodium Acetate,Bromine Solvents: Acetic Acid; 0 °C; Overnight,70 °C; 70 °C -> Rt
标题:Preparation Of Azaindazole Or Diazaindazole Derivatives As Alk,Abl And/or C-Sr Kinase Inhibitors For Treating Cancer,Inflammation And Neurodegenerative Diseases
参考文献:World Intellectual Property Organization]

7254-34-4 = 941294-54-8
反应条件:1.1 Reagents: Sodium Acetate,Bromine Solvents: Acetic Acid; 12 H,70 °C
标题:Preparation Of 4-(4-Methylpiperazin-1-Yl)-N-(5-(Pyridin-3-Yl)-1H-Pyrazolo[3,4-B]Pyridin-3-Yl)Benzamide Derivative As A Whitening Agent
参考文献:Korea]

= 941294-54-8 [标题:Reaction Conditions
标题:Preparation Of Azaindazole Or Diazaindazole Derivatives As Alk,Abl And/or C-Sr Kinase Inhibitors For Treating Cancer,Inflammation And Neurodegenerative Diseases
参考文献:France

📜3-氰基-2-甲氧基吡啶置于溴,Sodium Acetate,溶剂黄146体系中,化学反应 12.0H,以65%的收率获得产物5-溴-2-甲氧基烟腈
参考文献:4-(4-메틸피페라진-1-일)-N-(5-(피리딘-3-일)-1H-피라졸로[3,4-B]피리딘-3-일)벤즈아미드 유도체,또는 이의 약학적으로 허용 가능한 염의 미백용 소재 용도
标题:4-(4-메틸피페라진-1-일)-N-(5-(피리딘-3-일)-1H-피라졸로[3,4-B]피리딘-3-일)벤즈아미드 유도체,또는 이의 약학적으로 허용 가능한 염의 미백용 소재 용도
摘要:A Derivative Of 4-(4-Methylpiperazin-1-yl)-N-(5-(Pyridin-3-yl)-1H-Pyrazolo[3,4-B]Pyridin-3-yl)Benzamide,Or A Pharmaceutically Acceptable Salt Thereof For Use As A Whitening Material,Provided In One Aspect Of The Present Invention,The Whitening Composition Provided In The Present Invention Has An Excellent Effect Of Inhibiting The Promotion Of Melanin Production In Cells Even When Used In Small Amounts,And Can Be Effectively Used As A Skin Whitening Cosmetic Product,A Product For The Prevention,Improvement,And Treatment Of Melanin Pigment Excessive Deposition Diseases.